Effect of subcutaneous injection of a long-acting analogue of somatostatin (SMS 201–995) on plasma thyroid-stimulating hormone in normal human subjects
- 1 January 1988
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 42 (26), 2691-2699
- https://doi.org/10.1016/0024-3205(88)90245-7
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Long-Term Treatment of Acromegaly with the Somatostatin Analogue SMS 201–995New England Journal of Medicine, 1986
- PROLONGED TREATMENT OF ZOLLINGER-ELLISON SYNDROME BY LONG-ACTING SOMATOSTATINThe Lancet, 1986
- Long-Term Treatment of Acromegaly with the Somatostatin Analogue SMS 201–995New England Journal of Medicine, 1985
- THE INTERACTION OF HUMAN PANCREATIC GROWTH HORMONE RELEASING FACTOR 1–44 WITH SOMATOSTATIN IN VIVO IN NORMAL MANClinical Endocrinology, 1985
- Effect of Somatostatin in Necrolytic Migratory Erythema of GlucagonomaActa Medica Scandinavica, 1985
- Somatostatin inhibits prolactin release from the lactotroph primed with oestrogen and cyproterone acetate in manJournal of Endocrinology, 1984
- A sensitive immunoradiometric assay for serum thyroid stimulating hormone: a replacement for the thyrotrophin releasing hormone test?BMJ, 1984
- INFUSION OF GRADED CONCENTRATIONS OF SOMATOSTATIN IN MAN: PHARMACOKINETICS AND DIFFERENTIAL INHIBITORY EFFECTS ON PITUITARY AND ISLET HORMONESClinical Endocrinology, 1984
- SOMATOSTATIN‐28 AND SOMATOSTATIN‐14 SUPPRESSION OF ARGININE‐, INSULIN‐, AND TRH‐STIMULATED GH AND PRL SECRETION IN MANClinical Endocrinology, 1983
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982